7-benzyloxy-1-naphthaleneamine

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 7-benzyloxy-1-naphthaleneamine
• 英文别名: 8-aminonaphthalen-2-yl benzoate；(8-Aminonaphthalen-2-yl) benzoate
• 化学式: C₁₇H₁₃NO₂
• 分子量: 263.296
• InChiKey: MNCBDZBMSZJOGK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7-benzyloxy-1-naphthaleneamine 在 palladium on activated charcoal 吡啶 、 potassium permanganate 、 tris-(dibenzylideneacetone)dipalladium(0) 、 高氯酸 、 氢气 、 sodium hydride 、 2-二环己膦基-2'-(N,N-二甲胺)-联苯 作用下， 以 1,4-二氧六环 、 甲苯 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 26.5h， 生成 2-((carboxycarbonyl)(7-hydroxy-1-naphthyl)amino)benzoic acid
  参考文献：
  名称：

  Discovery and Structure−Activity Relationship of Oxalylarylaminobenzoic Acids as Inhibitors of Protein Tyrosine Phosphatase 1B

  摘要：

  Protein Tyrosine phosphatase 1B (PTP1B) has been implicated as a key negative regulator of both insulin and leptin signaling pathways. Using an NMR-based screening approach with 15N- and 13C-labeled PTP1B, we have identified 2,3-dimethylphenyloxalylaminobenzoic acid (1) as a general, reversible, and competitive PTPase inhibitor. Structure-based approach guided by X-ray crystallography facilitated the development of 1 into a novel series of potent and selective PTP1B inhibitors occupying both the catalytic site and a portion of the noncatalytic, second phosphotyrosine binding site. Interestingly, oral biovailability has been observed in rats for some compounds. Furthermore, we demonstrated in vivo plasma glucose lowering effects with compound 12d in ob/ob mice.

  DOI：

  10.1021/jm0205696
• 作为产物：
  描述：

  苯甲酰氯 在 (μ-oxo)bis[(1,2-ethanediamino-N,N'-bis(salicylidene))iron(III)] 、 三乙胺 作用下， 以 5,5-dimethyl-1,3-cyclohexadiene 、 二氯甲烷 为溶剂， 反应 36.33h， 生成 7-benzyloxy-1-naphthaleneamine
  参考文献：
  名称：

  μ-氧代-双核铁（III）催化脂肪族和芳香族氨基醇的O选择酰化和叔醇的酯交换反应

  摘要：

  开发了一种用于酯交换反应的高度化学选择性和反应性的μ-氧-双核铁（III）salen催化剂。发达的铁络合物催化脂肪族氨基醇的酰化反应，具有几乎完美的O选择性，即使使用活化酯，其化学选择性也更难控制。此外，首次实现了芳族氨基醇的O选择性酯交换。铁络合物的高活性使得能够使用空间上充斥的叔醇，包括前所未有的叔丁醇。

  DOI：

  10.1002/chem.201602801

文献信息

• [EN] NAPHTHYLUREA AND NAPHTHYLACETAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) ANTAGONISTS<br/>[FR] DERIVES AMINES
  申请人：BAYER AG

  公开号：WO2003014064A1

  公开（公告）日：2003-02-20

  Naphthylurea and naphthylacetamide derivatives of formula (I) which have vanilloid receptor 1 (VR1) antagonistic activity are disclosed, formula (I) wherein Y represents formula (II) and formula (III) and the variables Q, X, R6, R7, R8, R8a, R9, R10 and R11 are as defined in the claims. The compounds are useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, incontinence and/or inflammatory disorders.

  本文披露了公式(I)的萘基脲和萘基乙酰胺衍生物，其具有vanilloid受体1（VR1）拮抗活性，其中公式(I)中Y代表公式(II)和公式(III)，而变量Q、X、R6、R7、R8、R8a、R9、R10和R11如权利要求中所定义。这些化合物可用于预防和治疗与VR1活性相关的疾病，特别是用于治疗尿失禁、过度活动膀胱、慢性疼痛、神经病性疼痛、术后疼痛、类风湿性关节炎疼痛、神经痛、神经病、疼痛、神经损伤、缺血、神经退行性疾病、中风、失禁和/或炎症性疾病。
• Amine derivatives
  申请人：——

  公开号：US20040259875A1

  公开（公告）日：2004-12-23

  An amine derivative, its tautomeric or stereoisomeric form, or a salt thereof which has vanilloid receptor 1 (VR1) antagonistic activity, is disclosed. The amine derivative has an excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, incontinence and/or inflammatory disorders.

  本发明揭示了一种具有vanilloid receptor 1（VR1）拮抗活性的胺衍生物、其互变异构体或立体异构体形式或其盐。该胺衍生物具有优异的VR1拮抗活性，适用于预防和治疗与VR1活性相关的疾病，特别是用于治疗尿失禁、过度活动膀胱、慢性疼痛、神经痛、术后疼痛、类风湿性关节炎疼痛、神经痛、神经病、疼痛、神经损伤、缺血、神经退行性疾病、中风、失禁和/或炎症性疾病。
• COLGAN, STEPHEN T.;KRULL, IRA S.;DORSCHEL, CRAIG;BIDLINGMEYER, BRIAN A., J. CHROMATOGR. SCI., 26,(1988) N 10, C. 501-512
  作者：COLGAN, STEPHEN T.、KRULL, IRA S.、DORSCHEL, CRAIG、BIDLINGMEYER, BRIAN A.

  DOI：——

  日期：——
• NAPHTHYLUREA AND NAPHTHYLACETAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) ANTAGONISTS
  申请人：Bayer HealthCare AG

  公开号：EP1414788A1

  公开（公告）日：2004-05-06
• Discovery and Structure−Activity Relationship of Oxalylarylaminobenzoic Acids as Inhibitors of Protein Tyrosine Phosphatase 1B
  作者：Gang Liu、Bruce G. Szczepankiewicz、Zhonghua Pei、David A. Janowick、Zhili Xin、Philip J. Hajduk、Cele Abad-Zapatero、Heng Liang、Charles W. Hutchins、Stephen W. Fesik、Steve J. Ballaron、Mike A. Stashko、Tom Lubben、Amanda K. Mika、Bradley A. Zinker、James M. Trevillyan、Michael R. Jirousek

  DOI：10.1021/jm0205696

  日期：2003.5.1

  Protein Tyrosine phosphatase 1B (PTP1B) has been implicated as a key negative regulator of both insulin and leptin signaling pathways. Using an NMR-based screening approach with 15N- and 13C-labeled PTP1B, we have identified 2,3-dimethylphenyloxalylaminobenzoic acid (1) as a general, reversible, and competitive PTPase inhibitor. Structure-based approach guided by X-ray crystallography facilitated the development of 1 into a novel series of potent and selective PTP1B inhibitors occupying both the catalytic site and a portion of the noncatalytic, second phosphotyrosine binding site. Interestingly, oral biovailability has been observed in rats for some compounds. Furthermore, we demonstrated in vivo plasma glucose lowering effects with compound 12d in ob/ob mice.